Literature DB >> 27457374

Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein.

B Clarivet1, P Robin2, Y M Pers3, R Ferreira3, J Lebrun2, C Jorgensen3, D Hillaire-Buys2, V Brés2, J L Faillie2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27457374     DOI： 10.1007/s00228-016-2107-0

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  3 in total

1.  Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.

Authors:  Sebastian Härtter; Michael Koenen-Bergmann; Ashish Sharma; Gerhard Nehmiz; Ute Lemke; Wolfgang Timmer; Paul A Reilly
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

2.  Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice.

Authors:  G Hartmann; H Kim; M Piquette-Miller
Journal:  Int Immunopharmacol       Date:  2001-02       Impact factor: 4.932

3.  Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4.

Authors:  Hanaka Mimura; Kaoru Kobayashi; Linxiaoqing Xu; Mari Hashimoto; Yoko Ejiri; Masaya Hosoda; Kan Chiba
Journal:  Drug Metab Pharmacokinet       Date:  2014-09-28       Impact factor: 3.614
  3 in total
  5 in total

Review 1.  Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice.

Authors:  Nicola Ferri; Elisa Colombo; Marco Tenconi; Ludovico Baldessin; Alberto Corsini
Journal:  Pharmaceutics       Date:  2022-05-24       Impact factor: 6.525

2.  Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.

Authors:  John D Davis; Ashish Bansal; David Hassman; Bolanle Akinlade; Meng Li; Zhaoyang Li; Brian Swanson; Jennifer D Hamilton; A Thomas DiCioccio
Journal:  Clin Pharmacol Ther       Date:  2018-04-02       Impact factor: 6.875

Review 3.  Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.

Authors:  Haleh Rezaee; Fariba Pourkarim; Samira Pourtaghi-Anvarian; Taher Entezari-Maleki; Touraj Asvadi-Kermani; Masoud Nouri-Vaskeh
Journal:  Pharmacol Res Perspect       Date:  2021-02

Review 4.  A systematic review on disease-drug-drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling.

Authors:  Laura M de Jong; Sylvia D Klomp; Nicoline Treijtel; Robert Rissmann; Jesse J Swen; Martijn L Manson
Journal:  Br J Clin Pharmacol       Date:  2022-06-16       Impact factor: 3.716

Review 5.  The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia.

Authors:  Milo Gatti; Emanuel Raschi; Elisabetta Poluzzi; Cristian Martignani; Stefania Salvagni; Andrea Ardizzoni; Igor Diemberger
Journal:  Curr Heart Fail Rep       Date:  2020-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.